百悦泽®、索托克拉和BTK CDAC的数据(包括联用)表明:产品有望全面满足各类慢性淋巴细胞白血病患者未尽之需乳腺癌、肺癌和胃肠道癌领域的管线产品新数据极具前景,包括CDK4抑制剂、B7-H4 ADC和新型PRMT5抑制剂管线研发正处于令人振奋的关键转折点,未来18个月内将迎来20项里程碑进展美国加州圣卡洛斯——百济神州有限公司(纳斯达克代码:ONC;香港联交所代码:06160;上交所代码:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.